Title: Antibody avidity maturation favors SARS-CoV-2 convalescents over vaccinated individuals granting breadth in neutralizability and tolerance against variants

Authors: Yu Nakagama, Katherine Candray, Natsuko Kaku, Yuko Komase, Maria-Virginia Rodríguez-Funes, Rhina Dominguez, Tomoya Tsuchida, Hiroyuki Kunishima, Etsuko Nagai, Eisuke Adachi, Dieudonné Mumba Ngoyi, Mari Yamasue, Kosaku Komiya, Kazufumi Hiramatsu, Naoto Uemura, Yuki Sugiura, Mayo Yasugi, Yuka Yamagishi, Hiroshige Mikamo, Satoshi Shiraishi, Takehiro Izumo, Sachie Nakagama, Chihiro Watanabe, Yuko Nitahara, Evariste Tshibangu-Kabamba, Hiroshi Kakeya, Yasutoshi Kido

Author institutional affiliations:

a Department of Virology & Parasitology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan
b Research Center for Infectious Disease Sciences, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan
c Centro Nacional de Investigaciones Científicas de El Salvador (CICES), San Salvador, El Salvador
d Department of Respiratory Internal Medicine, St. Marianna University, Yokohama Seibu Hospital, Yokohama, Japan

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
19  e National Rosales Hospital, San Salvador, El Salvador
20  f El Salvador National Institute of Health, San Salvador, El Salvador
21  g Division of General Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan
22  h Department of Infectious Diseases, St. Marianna University School of Medicine, Kawasaki, Japan
23  i Department of Infectious Diseases and Applied Immunology, Institute of Medical Science, The University of Tokyo, Tokyo, Japan
24  j Institut National de Recherche Biomedicale, Kinshasa, Democratic Republic of the Congo
25  k Department of Respiratory Medicine and Infectious Diseases, Oita University Faculty of Medicine, Oita, Japan
26  l Center for Cancer Immunotherapy and Immunobiology, Kyoto University Graduate School of Medicine, Kyoto, Japan
27  m Graduate School of Veterinary Science, Osaka Metropolitan University, Osaka, Japan
28  n Asian Health Science Research Institute, Osaka Metropolitan University, Osaka, Japan
29  o Osaka International Research Center for Infectious Diseases, Osaka Metropolitan University, Osaka, Japan
30  p Department of Clinical Infectious Diseases, Aichi Medical University, Aichi, Japan
Department of Respiratory Medicine, Osaka City Juso Hospital, Osaka, Japan

Department of Respiratory Medicine, Japanese Red Cross Medical Center, Tokyo, Japan

Department of Infection Control Science, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan

Metropolitan University, Osaka, Japan

**Keywords:** SARS-CoV-2, Antibody maturation, Avidity, Neutralization breadth, Variants of concern

**Running title:** High-avidity SARS-CoV-2 IgG protectivity

**Address for correspondence (alternate):**

Yasutoshi Kido, MD, PhD (Yu Nakagama, MD, PhD)

Department of Parasitology, Graduate School of Medicine, Osaka Metropolitan University,

1-4-3 Asahi-machi, Abeno-ku, Osaka 545-8585, Japan

E-mail: kidoyasu@omu.ac.jp (nakagama.yu@omu.ac.jp)

**Type of manuscript**

Major article
Abstract—word count 246

Background

The durability and cross-neutralizability of protective antibodies against evolving SARS-CoV-2 variants are primary concerns in mitigating (re-)exposures. The role of antibody maturation, the process whereby selection of higher avidity antibodies augments host immunity, to determine SARS-CoV-2 neutralizability was investigated.

Methods

Sera collected from SARS-CoV-2 convalescent individuals at 2- or 10-months after recovery, and BNT162b2 vaccine recipients at 3 or 25 weeks post-vaccination, were analyzed. Anti-spike IgG avidity was measured on a urea-treated ELISA platform. Neutralizing ability of antibodies was assessed by surrogate virus neutralization. Fold change between variant and wild-type antigen neutralizability was calculated to infer breadth of neutralizability.

Results

Compared with early-convalescence, the avidity index of late-convalescent sera was significantly higher (median 37.7 (interquartile range 28.4–45.1) vs. 64.9 (57.5–71.5), p < 0.0001), indicative of progressive antibody maturation extending months beyond acute-phase illness. The urea-resistant, high-avidity fraction of IgG was best predictive of
neutralizability (Spearman’s r = 0.49 vs. 0.67 for wild-type; 0.18–0.52 vs. 0.48–0.83 for variants). Higher-avidity convalescent sera showed greater cross-neutralizability against SARS-CoV-2 variants (p < 0.001 for Alpha; p < 0.01 for Delta and Omicron). Vaccinees experienced delayed maturation kinetics, translating to limited breadth of neutralizability at week-25 post-vaccination which was only comparable to that of early-convalescence.

Conclusions

Avidity maturation grants broader neutralizability that is resilient against emerging SARS-CoV-2 variants. With immunopotentiation through repeat vaccinations becoming a pivotal strategy to accomplish herd immunity, understanding the variable longitudinal evolutions of the two building blocks of ‘hybrid immunity’ is crucial.
Introduction

Given the reported coronavirus disease 2019 (COVID-19) re-infections and vaccine breakthrough infections, it is unlikely that convalescent or vaccinated individuals will attain lifelong immune protection [1,2]. Therefore, the magnitude of partial immunity those individuals acquire is an important issue. In the convalescent phase and thereafter, circulating levels of neutralizing IgG that target the SARS-CoV-2 receptor binding domain (RBD) are highly correlated with residual protective immunity [3,4]. However, the durability of anti-spike IgGs and their potential cross-neutralizability against rapidly evolving severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants are primary concerns in mitigating future re-exposures [5].

Avidity maturation is the biological process whereby antigen-driven selection of higher affinity antibodies augments the host’s long-lasting protective immunity. Continuous antigen presentation at germinal centers promotes the fine-tuning of the antibody’s complementarity toward the epitope. The kinetics and potential implications of maturing antibody avidity in the context of immune protection against SARS-CoV-2 and its emerging variants of concern (VOCs) remains to be fully elucidated [6–8]. In the present study, we correlated the kinetics of serum antibody avidity maturation, which followed SARS-CoV-2
natural infections, as well as vaccine administrations, to the magnitude and breadth of in 

vitro neutralizability. Our observations provide a logical perspective on the variable 
durability and resilience of the two building blocks needed for the acquisition of ‘hybrid 
immunity’.

Materials and Methods

Human subjects and sample collection

Total 462 convalescent individuals, who had recovered from COVID-19 [9], were 
recruited at Osaka Metropolitan University and collaborating institutions preceding the 
emergence of the SARS-CoV-2 VOCs, comprising a mixed cohort from different regions, 
where the predominant genotypes belonged to B.1 or B.1.1 lineages [10,11]. Serum 
samples from recipients of the BNT162b2 SARS-CoV-2 mRNA vaccine were collected at 
week 3 and week 25 after the first dose. Analyses were conducted in accordance with the 
1964 Declaration of Helsinki and its later amendments. This research was approved by the 
Ethical Committee of Osaka Metropolitan University Graduate School of Medicine (#2020- 
003). All participants provided written informed consent prior to enrollment.

Anti-spike IgG measurement
Abbott SARS-CoV-2 IgG II Quant assays (Abbott, IL, USA, 6S6023) were run in accordance with the manufacturer’s instructions. Anti-SARS-CoV-2 IgG enzyme-linked immunosorbent assay (ELISA) (Euroimmun, Lübeck, Germany, EI 2606–9601) was performed in accordance with the manufacturer’s instructions.

**Avidity ELISA**

Serum samples were tested for their avidity towards the SARS-CoV-2 spike antigen using an ELISA-based assay (Euroimmun, Lübeck, Germany, EI 2606–9601) [12]. Samples were processed, in an extra pair of wells, with additional urea treatment (5.5 M for 10 min at 37°C) following the incubation of the spike antigen-coated plate with serum samples, to detach any low-avidity antibodies. The avidity index (AI) was calculated as follows: $AI = \frac{(OD_{450} \text{ of sample with } 5.5 \text{ M urea}) - (OD_{450} \text{ of negative control with } 5.5 \text{ M urea})}{(OD_{450} \text{ of sample without urea}) - (OD_{450} \text{ of negative control without urea})} \times 100 \%$. Serum samples were diluted 1:101 for analysis, except for the post-vaccine sera, which required a higher dilution of 1:201 to bring the $OD_{450}$ signals into linear range.

**Neutralizing ability**

Neutralizing ability against wild-type (WT) and VOC SARS-CoV-2 was quantified
using the GenScript SARS-CoV-2 sVNT (GenScript, Piscataway, NJ, USA, L00847-A), a competition ELISA-based surrogate virus neutralization test (sVNT). Obtained signals have been shown to strongly correlate with the results of the conventional live-virus neutralization test [13,14]. The assay protocol followed that of the manufacturer’s instructions. Serum samples and controls were pre-incubated to neutralize WT RBD (WT; GenScript, Z03594), or B.1.1.7 (Alpha; GenScript, Z03595), B.1.617.2 (Delta; GenScript, Z03614), or B.1.1.529 (Omicron; GenScript, Z03730) RBD variants conjugated with horseradish peroxidase. The inhibition rate (%inhibition) was calculated as follows: %inhibition = \{1 – (OD_{450} \text{ of sample}) / (OD_{450} \text{ of negative control})\} × 100 [%].

**Breadth of neutralizability**

For quantitative assessment of the serum antibodies’ abilities to cross-neutralize SARS-CoV-2 and its variants, the sVNT %inhibition values were converted to the linearly scaled WHO International Standard units, IU/mL [15,16]. We obtained a standard inhibitory dose-response curve by fitting the log-transformed IU/mL concentration values and their corresponding %inhibition data, obtained from testing four-fold serially diluted WHO International Standard (20/136) in the sVNT, to a four-parameter logistic equation (GraphPad Prism, version 9). The neutralizing titer (IU/mL) of the participants’ serum
samples, tested at optimized dilutions (up to 1:30, adjusted to bring the OD450 signals into quantitative range of the standard curves), was converted from sVNT %inhibition data by interpolation from the standard curve per different RBD antigen. The fold changes in neutralizing titer between the VOCs and WT (NT\textsubscript{Alpha}/NT\textsubscript{WT}, NT\textsubscript{Delta}/NT\textsubscript{WT}, and NT\textsubscript{Omicron}/NT\textsubscript{WT}) were calculated to serve as the index for the ‘breadth of neutralizability’. Similar indices have served as quantitative measures of relative neutralizing potency towards VOC strains [17].

**Statistical analysis**

Differences in titer, avidity, and the magnitude/breadth of neutralizing ability of sera were tested by Mann-Whitney test. For the longitudinal anti-spike IgG titer plot, a linear fit was performed, and Pearson’s correlation coefficient was calculated. Spearman’s correlation coefficient was calculated to assess the strength of the correlation between antibody titer and *in vitro* neutralizability. P-values less than 0.05 were considered statistically significant.

**Results**

**Serum anti-SARS-CoV-2 antibodies decay, while maturing in avidity, over time**
As recurrently reported, serum levels of circulating anti-spike IgG showed longitudinal decline in titer in SARS-CoV-2 convalescent individuals (Figure 1, panel A, Pearson’s $r = -0.28, p = 0.049$) [18]. To further investigate the qualitative evolution of serum antibodies, representative subsets of sera matched by their total anti-spike IgG titers (Figure 1, panel B, median OD$_{450}$ 1.12 (IQR 0.93–1.25) vs. 1.09 (IQR 0.89–1.26), $p = 0.98$) were selected from early- and late-convalescent ($n = 29$, median 8 (IQR 7–9) weeks and $n = 26$, median 37 (IQR 36–40) weeks post-onset of symptoms, respectively) phases, and compared of their serum antibody avidity characteristics. Polyclonal antibodies present in the late-convalescent sera were more avid against the SARS-CoV-2 spike antigen, and thus their OD$_{450}$ were relatively resistant to urea treatment (Figure 1, panel B). The difference in maturity of convalescent sera was reflected in the avidity index (AI), with that of late-convalescent sera demonstrating higher AIs (Figure 1, panel C, median AI 37.7 (IQR 28.4–45.1) vs. 64.9 (IQR 57.5–71.5), $p < 0.0001$), indicating a progressive maturation process that extends months beyond the acute phase of COVID-19.

**Higher-avidity antibodies exert broadened neutralizability against VOCs**

Next, we investigated the functional consequences of enhanced antibody avidity. Compared with the raw OD$_{450}$ values (Figure 2, panel A, upper), the urea-resistant OD$_{450}$
signals from the avidity ELISA (Figure 2, panel A, lower) better correlated with the inhibition rate (%inhibition) obtained from the surrogate sVNT. The results indicated a central role for high-affinity anti-spike IgG antibodies in determining in vitro neutralizability against SARS-CoV-2 WT and variant RBDs.

We next tested the hypothesis that serum antibody avidity determines the tolerability against RBD variations. As previously reported, the Alpha, Delta, and Omicron variants were more resistant to neutralization by convalescent sera, showing attenuated inhibition rates in the sVNT (Figure 2, panel B). To further compare the cross-neutralizability of individual sera against different VOCs, in other words the ‘breadth of neutralizability’, we attempted a linear scale conversion of the neutralizing titer by modifying previously employed methods [15]. Briefly, the neutralizing titer [IU/mL] of each convalescent sample was computed from their %inhibition values [%], through interpolation from standard curves that were generated by testing serially-diluted WHO International Standard (20/136) sera (Figure 3, panel A). The ‘breadth of neutralizability’ was expressed as the NT against the Alpha, Delta, and Omicron VOC RBDs (NT_{Alpha}, NT_{Delta}, and NT_{Omicron}, respectively) relative to the NT against the WT RBD (NT_{WT}) in fold changes. Interestingly, when NTs against SARS-CoV-2 VOCs were plotted against that of WT, with respect to the serum antibody’s AI, sera of higher AIs tended to show higher NT_{Alpha}, NT_{Delta}, and NT_{Omicron} values relative to
NT<sub>WT</sub> (Figure 3, panel B). Next, the fold change in NT against SARS-CoV-2 VOCs relative to the WT was compared between low- (below the 50th percentile) and high-avidity (50th percentile and above) serum samples. Higher-avidity sera showed greater fold change in NT across the different SARS-CoV-2 VOCs (Figure 3, panel C). Altogether, the results indicated that sera of higher AIs exhibited enhanced breadth of neutralizability and better tolerated the variations in SARS-CoV-2 RBD.

Vaccinees experience lesser extent of antibody maturation compared with convalescents

The variable kinetics of serum antibody avidity maturation between natural infection immunity and vaccine-elicited immune responses were assessed through analysis of sera from recipients of the BNT162b2 SARS-CoV-2 mRNA vaccine (vaccinees). Sera collected from vaccinees at week 3 (n = 9) and week 25 (n = 8) after the first dose were matched for their total anti-spike IgG titers (median OD<sub>450</sub> 1.37 (IQR 1.23–1.90) vs. 1.48 (IQR 1.20–1.75), p = 1.0), and their AIs were further compared with those of convalescent individuals (Figure 4, panel A). Serum antibodies present in the sera of week-25 vaccinees demonstrated significantly higher AIs compared with those of week-3 vaccinees (median 44.2 (IQR 38.3–47.4) vs 23.4 (IQR 16.9–26.6), p = 0.0002), indicating that the second dose
of the vaccine had boosted the hosts’ maturation of antibody avidity. However, the AIs of week-25 (approximate month 6) vaccinees were still only equivalent to those of month-2 early-convalescents, depicting a substantial lag in the avidity maturation process unique to the vaccine-elicited immune response (Figure 4, panel B).

**Contribution of the matured IgG fraction to neutralizability among vaccinees**

Interestingly, in contrast to the convalescent sera and the week-25 vaccinee sera, the neutralizability of the sera of week-3 vaccinees showed a relatively weak correlation (Spearman’s $r = 0.52$, $p = 0.16$) with their urea-resistant anti-spike IgG titer. The correlation was rather strong (Spearman’s $r = 0.87$, $p < 0.01$) when the levels of neutralizability were plotted against total anti-spike IgG titers. This indicates that high-avidity antibodies contribute less to neutralizability early in the vaccine response and become a stronger determinant only after the second dose (Spearman’s $r = 0.71$, $p = 0.06$). Reflecting their still insufficient degree of maturation, the breadth of neutralizability of the week-25 vaccinees’ sera was limited to an extent comparable to that of early-convalescent sera (Figure 4, panel C).

**Discussions**
Antibody avidity maturation in COVID-19 convalescents was observed as an ongoing process that surprisingly extended months beyond the acute phase. This finding supports the notion that SARS-CoV-2 proteins persist in tissues to continuously fuel the germinal centers for antigen presentation, even during late convalescence [19]. More importantly, the high-avidity neutralizing IgGs, which are the result of continuous B-cell evolution, remain in the circulation of late convalescents, fortifying for viral re-encounters by exerting enhanced cross-neutralizability against emerging SARS-COV-2 variants.

In theory, immature plasma cells produce antibodies that possess conformationally flexible antigen-binding surfaces, which at the cost of lowered specificity and affinity, are capable of recognizing diverse antigens (poly-reactivity hypothesis) [20]. In contrast, mature plasma cells produce antibodies of preorganized and rigid paratopes so as to take more energetically favorable configurations with improved complementarity against epitopes [21]. This general tendency towards paratope rigidification upon avidity maturation, while favorable in terms of enhancing specificity, is seemingly detrimental for broad cross-reactivity. In the case of SARS-CoV-2-neutralizing antibodies, however, our results show that high-avidity antibodies exert broader protection against evolving variants, granting long-lasting protective immunity. This paradoxical relationship between affinity maturation and the broadening in reactivity of SARS-CoV-2-neutralizing antibodies is
worthy of note. The molecular basis of B-cell evolution is explained by the acquisition of somatic hypermutations [22]. The aforementioned rigidification of paratopes is only one possible consequence of such somatic hypermutations. Mutations may lead to increased buried surface area upon complex formation, strengthening antibody-antigen binding. B-cells may alternatively acquire amino acid substitutions that result in better complementarity of the antigen binding site. Additive molecular contacts at the paratope-epitope interface, through the addition of novel polar or hydrophobic bonds, may also underlie the better complementarity [23]. The increase in variety of the structural determinants shall decrease the dependency of the paratope-epitope interaction on specific amino acid residues [24]. Thus, the latter diverse biophysical mechanisms of antibody affinity maturation all provide explanations to the tolerability of high-affinity antibodies against SARS-CoV-2 variants.

Given that the majority of the world’s population has relied largely on the SARS-CoV-2 vaccines for immunological protection, our secondary interest was how the vaccine-elicited immune responses were different from natural infection-acquired immunity. The kinetics of affinity maturation of SARS-CoV-2-specific antibodies have recently been shown to correlate with the longevity of immune protection following natural SARS-CoV-2 infection [25–27]. The here observed higher potency of the high-avidity antibodies in neutralizing SARS-CoV-2 may counter the longitudinal decay in quantity and explain the durability of
infection-acquired immune protection. Interestingly, compared with natural infection, we observed a substantial delay in the maturation process of vaccine-elicited antibodies. This was accompanied by still insufficient cross-neutralizability against SARS-CoV-2 variants even 6 months after vaccination. Large-scale clinical trials in real-world settings have shown greater protection associated with infection-acquired immunity than with vaccine-elicited immune responses [28,29]. The present study further enriches the evidence for and provides an immunological basis to the greater protection associated with infection-acquired immunity. Additionally, the urea-resistant fraction of the antibody titer was predictive of neutralizability only following the second dose of the vaccine. In contrast to the limited variety of epitopes recurrently targeted across convalescent individuals [30], the vaccine-elicited immune response is mapped to a broadened epitope landscape [31,32].

During the initial response to the SARS-CoV-2 vaccine, the majority of urea-resistant signals obtained from our avidity ELISA were possibly from a widely dispersed, non-neutralizing antibody repertoire that still dominated the week-3 vaccinees’ sera. The second vaccine dose seemingly facilitated the positive selection of neutralizing over non-neutralizing epitopes. Collectively, the dynamics of epitope selection, as well as avidity maturation, seem to radically differ among vaccinees and convalescents [33].

Furthermore, circulating IgG may serve as sources of passive
immunotherapeutics [34]. In such a context, their extent of maturity may affect cross-neutralizability and immunotherapy outcome. Immunotherapy using convalescent sera has unfortunately remained investigational for COVID-19, though expected beneficial for those with deficient active immunity [35,36]. To mitigate the emergence of immune-escaping variants in future pandemics, assessing avidity to stratify the potency of donated sera may be a reasonable strategy for effective immunotherapy.

Limitations of the present study include: (i) the serum samples were not serial collections from individuals, (ii) the cellular compartment was not studied, which also plays decisive roles in immune protection, and (iii) the observation period of vaccinees was limited, so the long-term consequences remain elusive.

In conclusion, the present study showed that the continuous process of avidity maturation, extending beyond late convalescence, grants broader neutralizability and robust protection that stand resilient against emerging SARS-CoV-2 variants. With immunopotentiation through repeat vaccinations becoming a pivotal strategy to accomplish herd immunity, understanding the longitudinal evolution of vaccine-induced immune responses and the incremental protective effects of booster vaccinations, that are to be also repeated in convalescent individuals (‘hybrid immunity’), remains critical.
This research was supported by the Japan Agency for Medical Research and Development [grant numbers JP20jk0110021 to Y.N., JP20wm0125003 and JP20he1122001 to Y.K.]; the Japan Society for the Promotion of Science KAKENHI [21K09078 to N.K., 22K15927 to Y.N.]; and the Osaka Metropolitan University Strategic Research Grant [grant number OCU-SRG2021_YR09 to Y.N.]. The authors also received support from the Osaka Metropolitan University Special Reserves Fund for COVID-19 and the Shinya Yamanaka Laboratory COVID-19 Private Fund.

The authors would like to thank all participants of the study and, for technical assistance, Mrs. Mika Oku from Osaka Metropolitan University. Data acquisition was partly performed at the Research Support Platform, Graduate School of Medicine, Osaka Metropolitan University.

Y.N. and Y.K. report equity ownership of Quantum Molecular Diagnostics, an Osaka Metropolitan University spinout targeting infectious diseases to develop innovative
diagnostics. Y.N. and Y.K. also report receiving financial support outside of this work from

Abbott Japan LLC, Japan.
References


[6] Bauer G. The potential significance of high avidity immunoglobulin G (IgG) for protective


National Institute for Biological Standards and Control. First WHO International Standard for anti-SARS-CoV-2 immunoglobulin, human. (NIBSC code: 20/136) Available at:


https://doi.org/10.1016/S1074-7613(00)80108-9.


https://doi.org/10.1146/annurev-immunol-020711-075032


https://doi.org/10.1056/nejmoa2118691.


https://doi.org/10.1038/s41586-021-03696-9.


Figure legends

(A)

Pearson’s $r = -0.28$
$ho = 0.049$

(B)

- month-2 convalescent
- month-10 convalescent
Figure 1. Evolution of anti-SARS-CoV-2 IgG in convalescent individuals. A) Anti-spike IgG levels of individuals observed across the convalescent phase, and their linear fit (solid red line) with 95% confidence intervals (dashed red lines). B) Resistance of the OD$_{450}$ signal against urea treatment in subsets of sera from early- (n = 29) and late-convalescent (n = 26) samples, matched by total anti-spike IgG titers. C) Avidity index of antibodies present in early- (n = 29) and late-convalescent (n = 26) sera. OD$_{450}$, optical density at 450 nm. Statistical significance: ****p < 0.0001.
Total IgG

- **Wuhan wild-type**
  - Spearman's \( r = 0.49^{***} \)
- **Alpha variant**
  - Spearman's \( r = 0.51^{****} \)
- **Delta variant**
  - Spearman's \( r = 0.52^{****} \)
- **Omicron variant**
  - Spearman's \( r = 0.18 \)

High-avidity IgG

- **Wuhan wild-type**
  - Spearman's \( r = 0.67^{****} \)
- **Alpha variant**
  - Spearman's \( r = 0.83^{****} \)
- **Delta variant**
  - Spearman's \( r = 0.82^{****} \)
- **Omicron variant**
  - Spearman's \( r = 0.48^{***} \)

Urea-resistant anti-spike IgG titer (OD\(_{450}\))

- **Delta variant**
  - Spearman's \( r = 0.82^{****} \)
- **Omicron variant**
  - Spearman's \( r = 0.48^{***} \)
- **Alpha variant**
  - Spearman's \( r = 0.83^{****} \)
- **Wuhan wild-type**
  - Spearman's \( r = 0.67^{****} \)
Figure 2. Central role of high-avidity IgG in neutralizing SARS-CoV-2.

A) Neutralizability of antibodies present in early- (n = 29) and late-convalescent sera (n = 26) against wild-type and variant SARS-CoV-2, as measured by surrogate virus neutralization, and plotted against total (upper) and urea-resistant, high-avidity anti-spike IgG titers (lower). B) Resistance of SARS-CoV-2 variants against neutralization by convalescent sera. OD₄₅₀, optical density at 450 nm. Statistical significance: ***p < 0.001, ****p < 0.0001.
Figure 3. Enhanced neutralization breadth of higher-avidity anti-SARS-CoV-2 IgG.

A) Four-parameter logistic standard curves for conversion of inhibition rates to neutralizing antibody titers in WHO International Standard units, IU/mL. B) Cross-neutralizability of convalescent sera against the Alpha (left), Delta (middle), and Omicron variants (right). The samples’ avidity indices are depicted according to the color scale shown. C) Relative inhibition potency towards SARS-CoV-2 variants indexed to the wild-type neutralizing titer, indicating the breadth of neutralizability per serum. Statistical significance: **p < 0.01, ***p < 0.001.
(A) Urea-resistant anti-spike IgG titer (OD$_{450}$) vs. Total anti-spike IgG titer (OD$_{450}$).

(B) Avidity index (%) distribution across different time points:
- Week 3 vaccinee
- Week 25 vaccinee
- Month 2 convalescent
- Month 10 convalescent

Statistical significance levels:
- **** p < 0.0001
- *** p < 0.001
- 0.14
Figure 4. Functional evolution of anti-SARS-CoV-2 IgG in recipients of the BNT162b2 SARS-CoV-2 mRNA vaccine.

A) Resistance of the OD_{450} signal against urea treatment in subsets of sera from vaccine recipients at week 3 (n = 9) and week 25 (n = 8) post-vaccination, matched by total anti-spike IgG titers. B) Avidity index of antibodies present in week-3 (n = 9) and week-25 (n = 8) vaccinees in comparison with convalescent individuals. C) Relative inhibition potency of week-25 vaccinee sera (n = 8) towards SARS-CoV-2 variants plotted against that of convalescent individuals. OD_{450}, optical density at 450 nm. Statistical significance: *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
(A) Urea-resistant anti-spike IgG titer (OD$_{450}$) vs total anti-spike IgG titer (OD$_{450}$). 

(B) Avidity index [%] vs Fold Change in NT (NT$_{Alphac}. NT_{Wt}$).

(C) Fold Change in NT (NT$_{Omicron}. NT_{Wt}$) vs Fold Change in NT (NT$_{Delta}. NT_{Wt}$).